Wed.Jan 17, 2024

article thumbnail

Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts

Fierce Pharma

Bayer is launching a sweeping business overhaul as the German conglomerate sees “no viable alternative.” | Bayer is launching a sweeping business overhaul that will “come at the expense of many managerial employees,” as the German conglomerate sees “no viable alternative.

304
304
article thumbnail

CMS Finalizes Rule Streamlining Prior Authorization Process

MedCity News

CMS finalized a rule on Wednesday that included set deadlines for affected payers to complete prior authorization requests. Several organizations came out in support of the rule.

117
117
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With $1.2B stock sale, GSK offloads more of its stake in consumer health spinoff Haleon

Fierce Pharma

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. | GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022.

Sales 224
article thumbnail

AMA President: Medicare Physician Pay Cuts Will Have ‘Dire’ Impact if Not Reversed

MedCity News

The Medicare physician pay cuts that went into effect January 1 is a “disaster for the profession,” said Dr. Jesse Ehrenfeld, president of the AMA, during an interview at CES 2024. Getting the pay cut reversed is a top priority for the organization.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

US agency nixes Seagen patent, handing Daiichi Sankyo a win in long-running Enhertu entanglement

Fierce Pharma

After years of patent litigation between cancer drug developers Daiichi Sankyo and Seagen, the U.S. Patent and Trademark office (U.S. PTO) has handed Daiichi the latest win in the saga. | After a Texas jury sided with Seagen a patent spat, the U.S. Patent and Trademark Office has invalidated the patent in question.

223
223
article thumbnail

Is General Catalyst Buying Summa Health a Good Idea? Only Time Will Tell

MedCity News

General Catalyst just announced its plans to acquire Summa Health, an Ohio-based health system. Leaders from across the healthcare industry aren’t sure how the deal will play out, given the novel nature of the deal and the involvement of one of the country’s most prominent VC firms.

More Trending

article thumbnail

Women’s health gap estimated at $1trn in new report

pharmaphorum

The disparity in access to healthcare between women and men around the world is often talked about but has never been given a dollar value – until now.

article thumbnail

PointClickCare Acquires CPSI’s Post-Acute EHR Subsidiary

MedCity News

CPSI sold American HealthTech — its subsidiary that provides an EHR platform for the post-acute care market — to post-acute health IT vendor PointClickCare. American HealthTech’s customers have already begun transitioning to PointClickCare’s platform.

Marketing 104
article thumbnail

New anti-smoking drug set for rapid NHS rollout

pharmaphorum

Oral cytisine therapy for smoking cessation from Consilient Health will launch in the UK next week, helping to alleviate a shortage of prescription drugs to help people quit

article thumbnail

Novel heart failure drug could halt disease progression

European Pharmaceutical Review

The small molecule heart failure drug acoramidis has potential in slowing or stopping the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), according to study data published in the New England Journal of Medicine. Findings from the Phase III trial ATTRibute-CM showed the novel drug is safe and can achieve near-complete stabilisation of TTR proteins, which play a key role in disease progression of ATTR-CM.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

How do you gain an employer’s attention in a medical sales interview?

Global Edge Recruiting

Global Edge Recruiting How do you gain an employer’s attention in a medical sales interview? How can you show an employer you have a winning spirit in a medical sales interview? Medical sales is about winning. In fact, just about every sales position is about winning. Winning the bid, winning the sale, winning the contract…it is all the same. In medical sales, you are always trying to win business for […] The post How do you gain an employer’s attention in a medical sales interview?

article thumbnail

The Prohibitive Economics of Weight Care

MedCity News

How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.

article thumbnail

First CRISPR drug Casgevy gets swift second approval

pharmaphorum

FDA has approved Vertex and CRISPR Therapeutics' Casgevy as first CRISPR based therapy for transfusion-dependent thalassaemia.

FDA 113
article thumbnail

Forta Health Rakes In $55M to Empower Family Caregivers

MedCity News

Forta Health raised $55 million in Series A funding on Wednesday. The startup offers a platform to help family caregivers quickly access care to manage their loved ones’ chronic conditions. The startup’s first area of focus is autism spectrum disorder (ASD).

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO

pharmaphorum

The US patent office has invalidated the only Seagen patent cited in a lawsuit claiming infringement by Daiichi Sankyo’s breast cancer therapy Enhertu.

105
105
article thumbnail

New Technology Adoption During Times of Crisis: 3 Key Lessons for Biopharma Innovators

MedCity News

In the face of these multifaceted threats, the need for innovative healthcare solutions becomes increasingly urgent. It underscores the vital role of the biopharmaceutical industry in not only addressing immediate health crises but also contributing to the broader resilience and well-being of humanity in times of adversity.

Biopharma 100
article thumbnail

Coya stretches lead drug’s development to Parkinson’s and dementia

Pharmaceutical Technology

Coya plans to file investigational new drug applications for COYA 302 in amyotrophic lateral sclerosis and frontotemporal dementia later this year.

Leads 98
article thumbnail

An enduring COVID mystery: Why some do fine and others die

PharmaVoice

The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Ban on Apple Watches with pulse oximetry renews in US

pharmaphorum

US federal court renews ban on Apple Watches with blood oxygen feature that infringes patents held by Masimo, but tech giant says it has a workaround

100
100
article thumbnail

Cell Therapy Startup With Stanford Roots Unveils $75M to Seek Inflammation Cures

MedCity News

Startup TrX1 develops cell therapies that function like a particular type of regulatory T cell, or Treg, whose role includes dampening inflammation and inducing long-term tolerance. Based on research from Stanford, TrX1’s lead program is a potential therapy for preventing graft-versus-host disease.

Leads 94
article thumbnail

Takeda gains US FDA approval for HYQVIA to treat CIDP

Pharmaceutical Technology

Takeda has gained approval from the US Food and Drug Administration for HYQVIA to treat chronic inflammatory demyelinating polyneuropathy.

article thumbnail

StemSight and ERS Genomics focus on collaboration

PharmaTimes

License agreement concerns development of cell therapies for corneal blindness

94
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA approves Vertex’s gene-edited therapy for beta thalassemia

Pharmaceutical Technology

The US FDA has approved Vertex's CASGEVY, a gene-edited cell therapy, to treat transfusion-dependent beta thalassemia.

FDA 98
article thumbnail

New Machine Learning Model May Accelerate Drug Development

Pharmaceutical Commerce

Researchers from the University of Cambridge collaborated with Pfizer to develop a platform combining automated experiments with artificial intelligence to predict chemical reactions.

52
article thumbnail

The evolving presence of AI in telemedicine for behavioural health

Pharmaceutical Technology

AI in telemedicine for behavioural health can revolutionise patient access to treatment, lower costs and identify urgent concerns.

article thumbnail

Gene-Edited Cell Therapy Casgevy Gains FDA Approval for Transfusion-Dependent Beta Thalassemia

PharmExec

Vertex Pharmaceuticals' and CRISPR Therapeutics’ Cas9 therapy Casgevy approved as a one-time treatment for transfusion-dependent beta thalassemia on the heels of its approval last month for sickle cell disease.

FDA 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Avoid “narrow national interest” in fighting next pandemic, WHO chief says

Pharmaceutical Technology

Speaking at Davos, WHO chief Dr. Ghebreyesus said learning lessons from the Covid-19 pandemic is a priority in fighting Disease X.

64
article thumbnail

HyQvia Gets FDA Approval for Chronic Inflammatory Demyelinating Polyneuropathy Maintenance

Pharmaceutical Commerce

Patients with chronic inflammatory demyelinating polyneuropathy administered HyQvia showed a statistically significant difference between relapse rates compared with placebo.

FDA 52
article thumbnail

Bupa is leveraging its unique position to develop IoT and AI features

Pharmaceutical Technology

The British health insurance and coverage provider is well-placed to invest in new technology due to its payment structure.

article thumbnail

FDA Approves CRISPR/Cas9 Gene-Edited Cell Therapy Casgevy for Transfusion-Dependent Beta Thalassemia

Pharmaceutical Commerce

The list price of Casgevy for transfusion-dependent beta thalassemia has yet to be released, however, the cost for the treatment in sickle cell disease is $2.2 million.

FDA 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A